Era of direct acting anti-viral agents for the treatment of hepatitis C

doi:10.4254/wjh.v10.i10.670

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6819)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

421

WORD

231

HTML

4482

Figures (1-1)

124

Tables (1-7)

145

Sum=5403

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

705

Download

711

Sum=1416

Oct 27, 2018 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Oct 27, 2018; 10(10): 670-684
Published online Oct 27, 2018. doi: 10.4254/wjh.v10.i10.670

Table 2 Genotype 1a and 1b infection - treatment-naïve (with compensated cirrhosis) and non-cirrhotic

No.	First line therapy	Alternative regimen
Genotype 1a infection - treatment-naïve and non-cirrhotic
1	Glecaprevir/Pibrentasvir (Mavyret) - 8 wk	Paritaprevir/ritonavir/ombitasvir and dasabuvir (in Viekira Pak and Viekira XR) with weight-based ribavirin - 12 wk
2	Elbasvir/Grazoprevir (Zepatier) for patients without baseline NS5A RAVs for Elbasvir - 12 wk	Simeprevir (Olysio) plus Sofosbuvir (Sovaldi) - 12 wk
3	Ledipasvir/Sofosbuvir (Harvoni) - 12 wk < Ledipasvir/Sofosbuvir (Harvoni) - 8 wk in non-black, HIV-uninfected individuals with serum HCV RNA < 6 million units/mL	Daclatasvir(Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk
4	Sofosbuvir/Velpatasvir (Epclusa) - 12 wk	Elbasvir/Grazoprevir (Zepatier) with weight-based ribavirin for patients with baseline NS5A RAVs for Elbasvir - 16 wk
Genotype 1a infection - treatment-naïve with compensated cirrhosis
1	Glecaprevir/Pibrentasvir (Mavyret) - 12 wk	Elbasvir/Grazoprevir (Zepatier) with weight-based ribavirin for patients with baseline NS5A RASs for Elbasvir - 16 wk
2	Elbasvir/Grazoprevir (Zepatier) for patients without baseline NS5A RAVs for Elbasvir - 12 wk
3	Ledipasvir/Sofosbuvir (Harvoni) - 12 wk
4	Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
Genotype 1b infection - treatment-naïve and non-cirrhotic
1	Glecaprevir/Pibrentasvir (Mavyret) - 8 wk	Paritaprevir/ritonavir/ombitasvir and dasabuvir (in Viekira Pak and Viekira XR) - 12 wk
2	Elbasvir/Grazoprevir (Zepatier) - 12 wk	Simeprevir (Olysio) plus Sofosbuvir (Sovaldi) - 12 wk
3	Ledipasvir/Sofosbuvir (Harvoni) - 12 wk < Ledipasvir/Sofosbuvir (Harvoni - 8 wk in non-black, HIV-uninfected individuals with serum HCV RNA < 6 million units/mL	Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk
4	Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
Genotype 1b infection - treatment-naïve with compensated cirrhosis
1	Glecaprevir/Pibrentasvir (Mavyret) - 12 wk	Paritaprevir/ritonavir/ombitasvir and dasabuvir (in Viekira Pak and Viekira XR) - 12 wk
2	Elbasvir/Grazoprevir (Zepatier - 12 wk
3	Ledipasvir/Sofosbuvir (Harvoni) - 12 wk
4	Sofosbuvir/Velpatasvir (Epclusa - 12 wk

RAVs: Resistance- associated variants; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus.

Citation: Ahmed M. Era of direct acting anti-viral agents for the treatment of hepatitis C. World J Hepatol 2018; 10(10): 670-684
URL: https://www.wjgnet.com/1948-5182/full/v10/i10/670.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i10.670